The cost-effectiveness of sequences of biological disease-modifying antirheumatic drug treatment in England for patients with rheumatoid arthritis who can tolerate methotrexate.

Stevenson, M.D. orcid.org/0000-0002-3099-9877, Wailoo, A.J. orcid.org/0000-0002-9324-1617, Tosh, J.C. et al. (8 more authors) (2017) The cost-effectiveness of sequences of biological disease-modifying antirheumatic drug treatment in England for patients with rheumatoid arthritis who can tolerate methotrexate. Journal of Rheumatology, 44 (7). pp. 973-980. ISSN 0315-162X

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2017 Journal of Rheumatology. Reproduced in accordance with the publisher's self-archiving policy.
Keywords: Arthritis, Rheumatoid; Antirheumatic agents; Cost-Benefit Analysis; Economics, Medical
Dates:
  • Accepted: 13 November 2016
  • Published (online): 1 July 2017
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Funding Information:
FunderGrant number
NATIONAL INSTITUTE FOR HEALTH RESEARCH14/25/02
Depositing User: Symplectic Sheffield
Date Deposited: 01 Dec 2016 14:38
Last Modified: 16 Jul 2018 10:27
Published Version: https://doi.org/10.3899/jrheum.160941
Status: Published
Publisher: Journal of Rheumatology
Refereed: Yes
Identification Number: https://doi.org/10.3899/jrheum.160941

Share / Export

Statistics